Skip to main content
SpringerLink
Log in

Marketing Aspects of Company-Sponsored Postmarketing Surveillance Studies

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • ASCPT (American Society for Clinical Pharmacology and Therapeutics), Pharmacoepidemiology Section. Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. Clinical Pharmacology and Therapeutics 40: 598, 1990

    Google Scholar 

  • Association of the British Pharmaceutical Industry. A report of the Post-marketing Surveillance Working Party. Post-marketing Surveillance Quadripartite Guidelines, 1991

    Google Scholar 

  • Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1: 379–385, 1980

    Google Scholar 

  • Corstjens M. Marketing strategy in the pharmaceutical industry, 1st ed., p. 223, Chapman & Hall, 1991

    Google Scholar 

  • Editorial. New PMS guidelines in Spain. Scrip No. 1574: 9, 1990

  • Editorial. UK MCA concern about PMS studies. Scrip No. 1667: 2-3, 1991

  • Faich GA. Postmarketing surveillance: lessons learned. Drug Information Journal 25: 531–535, 1991

    Article  Google Scholar 

  • Faich GA, Guess HA, Kuritsky JM. Postmarketing surveillance for drug safety. In Cato AE (Ed.) Clinical trials and tribulations, Marcel Dekker, 1988

    Google Scholar 

  • Gordon AJ, Petrick RJ. Worldwide regulations for manufacturers on clinical safety surveillance of drugs. Drug Information Journal 26: 1–15, 1992

    Article  Google Scholar 

  • Inman WHW. PEM 2000, Drug Safety Research Unit PEM News 7: 7, 1991

    Google Scholar 

  • Joint Committee of ABPI, BMA, CSM and RCGP. Guidelines on postmarketing surveillance. British Medical Journal 296: 399–400, 1988

    Article  Google Scholar 

  • Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Statistics in Medicine 10: 577–582, 1991

    Article  PubMed  CAS  Google Scholar 

  • Rawlins MD. Postmarketing surveillance of adverse reactions to drugs. British Medical Journal 288: 879–880, 1984

    Article  PubMed  CAS  Google Scholar 

  • Richard BW, Melville A, Lasagna L. Postapproval research as a condition of approval: an update, 1985–1986. Journal of Clinical Research and Drug Development 3: 247–257, 1989

    Google Scholar 

  • Rossi AC, Knapp DE, Anello C, O’Neill RT, Graham CF, et al. Discovery of adverse drug reactions: a comparison of selected phase IV studies with spontaneous reporting methods. Journal of the American Medical Association 249: 2226–2228, 1983

    Article  PubMed  CAS  Google Scholar 

  • Rossi AC, Knapp DE, Anello C, O’Neill RT, Graham CF, et al. Postmarketing drug surveillance. Journal of the American Medical Association 251: 729–730, 1984

    Article  Google Scholar 

  • Schrogie JJ. Concordance of clinical and marketing objectives in phase IV. In Burley et al. (Eds) The focus for pharmaceutical knowledge. Proceedings of the 6th International Meeting of Pharmaceutical Physicians, pp. 119–124, June 1987

  • Spitzer WO. Epidemiology and drug safety. Proceedings of the Symposium Tost Registration Studies and Marketing — Europe 1992’, London, September 27, 1991

  • Stephens MDB. Pharmaceutical company viewpoint. In Walker & Goldberg (Eds) Monitoring for adverse drug reactions, pp. 119–125, MTP Press Ltd, Lancaster, 1984

    Google Scholar 

  • Strom BL. Pharmacoepidemiology, p. 200, Churchill Livingstone, 1989

    Google Scholar 

  • Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. British Medical Journal 304: 1470–1472, 1992

    Article  PubMed  CAS  Google Scholar 

  • Weber JCP. Epidemiology of adverse reactions to non-steroidal anti-inflammatory drugs. In Rainsford & Velo (Eds) Advances in inflammation research, Vol. 6, pp. 1–7, Raven Press, New York, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 49 King’s Court, Bishop’s Stortford, Hertfordshire, CM23 2AB, England

    Myles D. B. Stephens

Authors
  1. Myles D. B. Stephens
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stephens, M.D.B. Marketing Aspects of Company-Sponsored Postmarketing Surveillance Studies. Drug-Safety 8, 1–8 (1993). https://doi.org/10.2165/00002018-199308010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199308010-00001

Keywords

Search

Navigation